NCT03123835Enrolling by invitation
Outcome Analysis of POEM and Endoluminal Therapies
Outcome Analysis of Endoluminal Therapies for Gastrointestinal Conditions Compared to Current Treatment Paradigms
Source: ClinicalTrials.gov · Last updated 5 Dec 2025
Brief summary (registry, in English)
Evaluation of current and newly developed endoluminal therapies in the management of Upper and Lower GI conditions.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 5 Apr 2016
- Start date
- 1 Mar 2016
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- University of California, Davis
- Diseases
- Obesity
- NCT number
- NCT03123835
What you commit to
- Study type: Interventional
- Planned participants: 500
- From 1 Mar 2016 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Adults unable to consent
- Individuals that do not meet inclusion criteria or qualify for endoluminal treatment paradigms and internees.
Who the study is looking for
- Adult male and female patients 18-80 years of age
- Meet the criteria for surgery of benign and/or malignant gastrointestinal pathology(s)
- Gastrointestinal Reflux Disease
- Achalasia
- Barrett's Esophagus
- Post Bariatric Surgery conditions
- Other gastrointestinal and postsurgical disorders.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Univesity of California Davis Health System Coordinator of this site? Confirm its status | Sacramento | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.